Inter-Organ Communication Research Team, Institute for Life and Medical Sciences, Kyoto University, 54 Kawahara-cho, Shogoin Sakyo-ku, Kyoto, 606-8507, Japan.
Mathematical Informatics Laboratory, Division of Information Science, Nara Institute of Science and Technology, 8916-5 Takayama-cho, Ikoma, Nara, 630-0192, Japan.
Br J Cancer. 2024 Apr;130(6):1023-1035. doi: 10.1038/s41416-023-02527-0. Epub 2024 Jan 18.
Triple-negative breast cancer (TNBC) is the most heterogeneous breast cancer subtype. Partly due to its heterogeneity, it is currently challenging to stratify TNBC patients and predict treatment outcomes.
In this study, we examined blood cytokine profiles of TNBC patients throughout treatments (pre-treatment, during chemotherapy, pre-surgery, and 1 year after the surgery in a total of 294 samples). We analyzed the obtained cytokine datasets using weighted correlation network analyses, protein-protein interaction analyses, and logistic regression analyses.
We identified five cytokines that correlate with good clinical outcomes: interleukin (IL)-1α, TNF-related apoptosis-inducing ligand (TRAIL), Stem Cell Factor (SCF), Chemokine ligand 5 (CCL5 also known as RANTES), and IL-16. The expression of these cytokines was decreased during chemotherapy and then restored after the treatment. Importantly, patients with good clinical outcomes had constitutively high expression of these cytokines during treatments. Protein-protein interaction analyses implicated that these five cytokines promote an immune response. Logistic regression analyses revealed that IL-1α and TRAIL expression levels at pre-treatment could predict treatment outcomes in our cohort.
We concluded that time-series cytokine profiles in breast cancer patients may be useful for understanding immune cell activity during treatment and for predicting treatment outcomes, supporting precision medicine.
The study has been registered with the University Hospital Medical Information Network Clinical Trials Registry ( http://www.umin.ac.jp/ctr/index-j.htm ) with the unique trial number UMIN000023162. The association Japan Breast Cancer Research Group trial number is JBCRG-22. The clinical outcome of the JBCRG-22 study was published in Breast Cancer Research and Treatment on 25 March 2021. https://doi.org/10.1007/s10549-021-06184-w .
三阴性乳腺癌(TNBC)是最具异质性的乳腺癌亚型。部分由于其异质性,目前对 TNBC 患者进行分层和预测治疗结果具有挑战性。
在这项研究中,我们在 294 个样本中检测了 TNBC 患者在整个治疗过程中的血液细胞因子谱(治疗前、化疗期间、手术前和手术后 1 年)。我们使用加权相关网络分析、蛋白质-蛋白质相互作用分析和逻辑回归分析来分析获得的细胞因子数据集。
我们鉴定出五个与良好临床结果相关的细胞因子:白细胞介素(IL)-1α、肿瘤坏死因子相关凋亡诱导配体(TRAIL)、干细胞因子(SCF)、趋化因子配体 5(CCL5 也称为 RANTES)和 IL-16。这些细胞因子的表达在化疗期间下降,然后在治疗后恢复。重要的是,具有良好临床结果的患者在治疗过程中这些细胞因子的表达持续较高。蛋白质-蛋白质相互作用分析表明,这五个细胞因子促进免疫反应。逻辑回归分析表明,治疗前 IL-1α 和 TRAIL 的表达水平可以预测我们队列中的治疗结果。
我们得出结论,乳腺癌患者的时间序列细胞因子谱可能有助于了解治疗期间免疫细胞的活性,并预测治疗结果,支持精准医学。
该研究已在日本大学医院医疗信息网络临床试验注册中心(http://www.umin.ac.jp/ctr/index-j.htm)注册,注册号为 UMIN000023162。日本乳腺癌研究组的关联号为 JBCRG-22。JBCRG-22 研究的临床结果于 2021 年 3 月 25 日在《乳腺癌研究与治疗》杂志上发表。https://doi.org/10.1007/s10549-021-06184-w。